中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.021 seconds)

    COMPOUNDS AND METHODS
    1.
    发明申请
    COMPOUNDS AND METHODS 审中-公开

    公开(公告)号：US20170291904A1

    公开(公告)日：2017-10-12

    申请号：US15512005

    申请日：2015-09-17

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Hailin ZHENG ,  Jun ZHAO ,  Lawrence WENNOGLE

    IPC: C07D487/14

    CPC classification number: C07D487/14

    Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.

    ORGANIC COMPOUNDS
    3.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号：US20150072965A1

    公开(公告)日：2015-03-12

    申请号：US14539859

    申请日：2014-11-12

    Applicant: Intra-Cellular Therapies, Inc.

    Inventor： Peng LI ,  Jun ZHAO ,  Hailin ZHENG ,  Lawrence WENNOGLE

    IPC: C07D487/14 ,  A61K45/06 ,  A61K31/165 ,  A61K31/519

    CPC classification number: C07D487/14 ,  A61K31/165 ,  A61K31/519 ,  A61K31/5365 ,  A61K45/06

    Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.

    Abstract translation: 任选取代的4,5,7,8-四氢 - （任选4-氧代，4-硫代或4-亚氨基）-2H-咪唑并[1,2-a]吡咯并[3,4-e]嘧啶或4,5 ，7,8,9-五氢 - （任选4-氧代，4-硫代或4-亚氨基）-2H-嘧啶并[1,2-a]吡咯并[3,4-e]嘧啶化合物或式 ），其生产方法，它们作为药物的用途和包含其的药物组合物。

    ORGANIC COMPOUNDS
    4.
    发明申请
    ORGANIC COMPOUNDS 有权

    公开(公告)号：US20170217975A1

    公开(公告)日：2017-08-03

    申请号：US15502455

    申请日：2015-08-06

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Hailin ZHENG ,  Jun ZHAO ,  Lawrence P. WENNOGLE

    IPC: C07D487/14

    CPC classification number: C07D487/14

    Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

    ORGANIC COMPOUNDS
    6.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号：US20150080357A1

    公开(公告)日：2015-03-19

    申请号：US14296145

    申请日：2014-06-04

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Jun ZHAO ,  Hailin ZHENG ,  Lawrence WENNOGLE

    IPC: C07D487/14 ,  A61K31/5575 ,  A61K31/519

    CPC classification number: C07D487/14 ,  A61K31/519 ,  A61K31/5575 ,  A61K45/06

    Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-thioxo or 4-imino)-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

    Abstract translation: 任选取代的4,5,7,8-四氢 - （任选4-硫代或4-亚氨基） - （1H或2H） - 咪唑并[1,2-a]吡唑并[4,3-e]嘧啶或4,5 ，7,8,9-五氢 - （任选的4-硫代或4-亚氨基） - （1H或2H） - 嘧啶并[1,2-a]吡唑并[4,3-e]嘧啶化合物或式 ），其生产方法，它们作为药物的用途以及包含它们的药物组合物。

    ORGANIC COMPOUNDS
    7.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号：US20140148421A1

    公开(公告)日：2014-05-29

    申请号：US14169352

    申请日：2014-01-31

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Jun ZHAO ,  Hailin ZHENG ,  Lawrence WENNOGLE

    IPC: A61K31/519 ,  A61K45/06 ,  C07D487/14

    CPC classification number: C07D487/14 ,  A61K31/165 ,  A61K31/519 ,  A61K31/5365 ,  A61K45/06

    Abstract: Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.

    Abstract translation: 任选取代的4,5,7,8-四氢 - （任选4-氧代，4-硫代或4-亚氨基）-2H-咪唑并[1,2-a]吡咯并[3,4-e]嘧啶或4,5 ，7,8,9-五氢 - （任选4-氧代，4-硫代或4-亚氨基）-2H-嘧啶并[1,2-a]吡咯并[3,4-e]嘧啶化合物或式 ），其生产方法，它们作为药物的用途和包含其的药物组合物。

    ORGANIC COMPOUNDS
    8.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号：US20140005155A1

    公开(公告)日：2014-01-02

    申请号：US14020016

    申请日：2013-09-06

    Applicant: INTRA-CELLULAR THERAPIES, INC

    Inventor： Peng LI ,  Jun ZHAO ,  Hailin ZHENG ,  Lawrence P. WENNOGLE

    IPC: C07D487/14 ,  A61K45/06 ,  A61K31/5025

    CPC classification number: C07D487/14 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/529 ,  A61K31/5575 ,  A61K45/06 ,  C07D487/04

    Abstract: Optionally substituted 3-(thio, sulfinyl or sulfonyl)-7,8-dihydro-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or a substituted 3-(thio, sulfinyl or sulfonyl)-7,8,9-trihydro-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

    Abstract translation: 任选取代的3-（硫代亚磺酰基或磺酰基）-7,8-二氢 - （1H或2H） - 咪唑并[1,2-a]吡唑并[4,3-e]嘧啶-4（5H） - 酮或 取代的3-（硫代亚磺酰基或磺酰基）-7,8,9-三氢 - （1H或2H） - 嘧啶并[1,2-a]吡唑并[4,3-e]嘧啶-4（5H） - 酮化合物 或式（I）的化合物，其制备方法，它们作为药物的用途以及包含它们的药物组合物。

    COMPOUNDS AND METHODS
    9.
    发明申请
    COMPOUNDS AND METHODS 审中-公开

    公开(公告)号：US20190144460A1

    公开(公告)日：2019-05-16

    申请号：US16186272

    申请日：2018-11-09

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Hailin ZHENG ,  Jun ZHAO ,  Lawrence WENNOGLE

    IPC: C07D487/14

    Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.

Patent Agency Ranking